Marker Therapeutics, Inc.

Monthly Archives: July 2017

New Options in Cancer Care

A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.

Read More

TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology

Hear from Randal H. Henderson, MD,Professor,Department of Radiation Oncology and Associate Medical Director at the UF Health Proton Therapy Institute, and enjoy a panel discussion led by Glynn Wilson, PhD, Chairman & CEO of TapImmune, Inc.

Read More

Q&A with Director of CMC Operations at TapImmune Inc. (TPIV), Robin McCallum

Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.

Read More